{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:02:45Z","timestamp":1771952565973,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.conctc.2026.101611","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:44:37Z","timestamp":1770223477000},"page":"101611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimization of patient and site engagement in the SYNCHRONIZE\u2122 phase 3 clinical trial program for survodutide in obesity through clinical trial simulation"],"prefix":"10.1016","volume":"49","author":[{"given":"Domenica M.","family":"Rubino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivi\u00ebnne","family":"van de Walle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baanstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Dani\u00ebls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Recaldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Nadglowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.conctc.2026.101611_bib1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13063-017-2099-9","article-title":"Barriers to the conduct of randomised clinical trials within all disease areas","volume":"18","author":"Djurisic","year":"2017","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.conctc.2026.101611_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","article-title":"Barriers for conducting clinical trials in developing countries- a systematic review","volume":"17","author":"Alemayehu","year":"2018","journal-title":"Int. J. Equity Health"},{"issue":"1","key":"10.1016\/j.conctc.2026.101611_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1634\/theoncologist.2013-0290","article-title":"Barriers and challenges to global clinical cancer research","volume":"19","author":"Seruga","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.conctc.2026.101611_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/AMEP.S14103","article-title":"Physician participation in clinical research and trials: issues and approaches","volume":"2","author":"Rahman","year":"2011","journal-title":"Adv. Med. Educ. Pract."},{"issue":"9","key":"10.1016\/j.conctc.2026.101611_bib5","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1200\/JOP.19.00662","article-title":"Barriers to participation in therapeutic clinical trials as perceived by community oncologists","volume":"16","author":"Wong","year":"2020","journal-title":"JCO Oncol. Pract."},{"issue":"17-18","key":"10.1016\/j.conctc.2026.101611_bib6","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/jocn.12145","article-title":"Clinical trial recruitment \u2013 a complex intervention?","volume":"22","author":"Tramm","year":"2013","journal-title":"J. Clin. Nurs."},{"issue":"11","key":"10.1016\/j.conctc.2026.101611_bib7","doi-asserted-by":"crossref","DOI":"10.2196\/22179","article-title":"Online patient recruitment in clinical trials: systematic review and meta-analysis","volume":"22","author":"Br\u00f8gger-Mikkelsen","year":"2020","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.conctc.2026.101611_bib10","article-title":"Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry","year":"2020","journal-title":"Food and Drug Administration staff, and other stakeholders"},{"issue":"2","key":"10.1016\/j.conctc.2026.101611_bib11","article-title":"Recruitment and retention of healthy women with obesity for a psychophysiological study before and after weight loss: insights, challenges, and suggestions","volume":"11","author":"Bhammar","year":"2021","journal-title":"J. Obes. Weight Loss Ther."},{"issue":"7","key":"10.1016\/j.conctc.2026.101611_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13436","article-title":"A systematic review examining socioeconomic factors in trials of interventions for men that report weight as an outcome","volume":"23","author":"McDonald","year":"2022","journal-title":"Obes. Rev."},{"issue":"6","key":"10.1016\/j.conctc.2026.101611_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2969","article-title":"Global public attitudes about clinical research and patient experiences with clinical trials","volume":"1","author":"Anderson","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.conctc.2026.101611_bib14","volume":"vol. 5","author":"Hearld","year":"2017"},{"issue":"3","key":"10.1016\/j.conctc.2026.101611_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13687","article-title":"Clinical trials: predictors of knowledge and attitudes towards participation","volume":"75","author":"Awwad","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"21","key":"10.1016\/j.conctc.2026.101611_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192113832","article-title":"Recruiting and engaging women of reproductive age with obesity: insights from A mixed-methods study within A trial","volume":"19","author":"Killeen","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"1","key":"10.1016\/j.conctc.2026.101611_bib17","first-page":"10","article-title":"Enhancing the incorporation of the patient's voice in drug development and evaluation, research involvement and engagement","volume":"4","author":"Chalasani","year":"2018"},{"issue":"3","key":"10.1016\/j.conctc.2026.101611_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jval.2016.10.003","article-title":"Emerging guidelines for patient engagement in research","volume":"20","author":"Kirwan","year":"2017","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.conctc.2026.101611_bib19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.clinthera.2019.06.006","article-title":"Using patient advisory boards to solicit input into clinical trial design and execution","volume":"41","author":"Anderson","year":"2019","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.conctc.2026.101611_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00602-2022","article-title":"Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations","volume":"9","author":"Jones","year":"2023","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.conctc.2026.101611_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064159","article-title":"Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study","volume":"13","author":"Boisvert-Huneault","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.conctc.2026.101611_bib22","first-page":"1","article-title":"Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials, research involvement and engagement","volume":"10","author":"Furlong","year":"2024"},{"key":"10.1016\/j.conctc.2026.101611_bib23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/PPA.S137416","article-title":"Simulating clinical trial visits yields patient insights into study design and recruitment","volume":"11","author":"Lim","year":"2017","journal-title":"Patient Prefer. Adherence"},{"issue":"11","key":"10.1016\/j.conctc.2026.101611_bib24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/acr.23802","article-title":"Mock recruitment for the study of antimalarials in an incomplete lupus erythematosus trial","volume":"71","author":"Karp","year":"2019","journal-title":"Arthritis Care Res."},{"issue":"1","key":"10.1016\/j.conctc.2026.101611_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/oby.24184","article-title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE\u2122-1 and -2)","volume":"33","author":"Wharton","year":"2025","journal-title":"Obesity"},{"issue":"12","key":"10.1016\/j.conctc.2026.101611_bib26","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jchf.2024.09.004","article-title":"Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"JACC Heart Fail"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:20:44Z","timestamp":1771950044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865426000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":24,"alternative-id":["S2451865426000189"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101611","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of patient and site engagement in the SYNCHRONIZE\u2122 phase 3 clinical trial program for survodutide in obesity through clinical trial simulation","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101611"}}